VIGATO, CHIARA
VIGATO, CHIARA
SCIENZA E TECNOLOGIA DEL FARMACO
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer
2023-01-01 Chiara Vigato, Agnese Chiara Pippione, Stefano Sainas, Iole Mannella, Laura Bertarini, Sandra Kovachka, Barbara Rolando, Osman Asghar Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3)
2019-01-01 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3)
2019-01-01 Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi
Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization
2021-01-01 Martino Elena, Villella Noemi, Vigato Chiara, Cerrina Matteo, Bersani Matteo, Giorgis Marta, Sainas Stefano, Boschi Donatella, Lolli Marco Lucio
Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH)
2024-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Agnese C. Pippione, Alice Passoni, Renzo Bagnati, Paola Circosta, Riccardo Miggiano, Marta Alberti , Donatella Boschi, and Marco L. Lolli
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER
2023-01-01 Agnese C. Pippione, Stefano Sainas, Chiara Vigato, Iole Mannella, Irene Castellino, Sandra Kovachka, Mariia Iakovleva, Barbara Rolando, Tomasz Wrobel, Osman A. Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco L. Lolli, Donatella Boschi
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold
2022-01-01 Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Chiara Vigato, Agnese Chiara Pippione, Donatella Boschi, Giuseppe Saglio, Marco Lucio Lolli
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold
2022-01-01 M. Giorgis, S. Sainas, P.Circosta, A. Passoni, R. Bagnati, M. Marraudino, B. Bonaldo, S. Gotti, C. Vigato, A.C.Pippione, D. Boschi, G. Saglio, M.L. Lolli
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias
2021-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Marta Alberti, Agnese Chiara Pippione, Riccardo Miggiano, Davide Ferraris, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias
2021-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Marta Alberti, Agnese Chiara Pippione, Riccardo Miggiano, Davide Ferraris, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold
2021-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer
2022-01-01 Chiara Vigato, Agnese Chiara Pippione, Iole Mannella, Mariia Iakovleva, Stefano Sainas, Simonetta Oliaro Bosso, Barbara Rolando, Sandra Kovachka, Francesca Spyrakis, Marco Lucio Lolli, Donatella Boschi
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer
2021-01-01 Mannella, Iole, Vigato, Chiara, Pasha, Rabia; Pippione Agnese Chiara, Sainas, Stefano, Oliaro Bosso Simonetta; Rolando, Barbara; Kovachka, Sandra, Spyrakis, Francesca; Boschi, Donatella, Lolli. Marco Lucio
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies
2023-01-01 Iole Mannella, Chiara Vigato, Stefano Sainas, Marco Lucio Lolli, Donatella Boschi
Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies
2023-01-01 Iole Mannella, Chiara Vigato, Stefano Sainas, Marco Lucio Lolli, Donatella Boschi
Overcoming of metabolic issues in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase: the story of MEDS700
2024-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Agnese Chiara Pippione, Alice Passoni, Renzo Bagnati, Paola Circosta, Marta Alberti, Riccardo Miggiano, Donatella Boschi, Marco Lucio Lolli
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic
2022-01-01 Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Riccardo Miggiano, Davide Ferraris, Marta Alberti, Agnese Chiara Pippione, Chiara Vigato, Donatella Boschi, Giuseppe Saglio, Marco Lucio Lolli
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic
2022-01-01 Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Riccardo Miggiano, Davide Ferraris, Marta Alberti, Agnese Chiara Pippione, Chiara Vigato, Donatella Boschi, Giuseppe Nicola Saglio, Marco Lucio Lolli
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues
2021-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione; Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues
2021-01-01 Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer | 2023 | Chiara Vigato, Agnese Chiara Pippione, Stefano Sainas, Iole Mannella, Laura Bertarini, Sandra Kovachka, Barbara Rolando, Osman Asghar Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) | 2019 | Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro-Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) | 2019 | Chiara Vigato, Agnese Chiara Pippione, Sandra Kovachka, Francesca Spyrakis, Martina Daga, Simonetta Oliaro Bosso, Marco Lucio Lolli, Donatella Boschi | |
| Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization | 2021 | Martino Elena, Villella Noemi, Vigato Chiara, Cerrina Matteo, Bersani Matteo, Giorgis Marta, Sainas Stefano, Boschi Donatella, Lolli Marco Lucio | |
| Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) | 2024 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Agnese C. Pippione, Alice Passoni, Renzo Bagnati, Paola Circosta, Riccardo Miggiano, Marta Alberti , Donatella Boschi, and Marco L. Lolli | |
| HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER | 2023 | Agnese C. Pippione, Stefano Sainas, Chiara Vigato, Iole Mannella, Irene Castellino, Sandra Kovachka, Mariia Iakovleva, Barbara Rolando, Tomasz Wrobel, Osman A. Mirza, Karla Frydenvang, Francesca Spyrakis, Simonetta Oliaro-Bosso, Marco L. Lolli, Donatella Boschi | |
| Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold | 2022 | Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Chiara Vigato, Agnese Chiara Pippione, Donatella Boschi, Giuseppe Saglio, Marco Lucio Lolli | |
| Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold | 2022 | M. Giorgis, S. Sainas, P.Circosta, A. Passoni, R. Bagnati, M. Marraudino, B. Bonaldo, S. Gotti, C. Vigato, A.C.Pippione, D. Boschi, G. Saglio, M.L. Lolli | |
| Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias | 2021 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Marta Alberti, Agnese Chiara Pippione, Riccardo Miggiano, Davide Ferraris, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli | |
| Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias | 2021 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Marta Alberti, Agnese Chiara Pippione, Riccardo Miggiano, Davide Ferraris, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli | |
| Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold | 2021 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli | |
| New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer | 2022 | Chiara Vigato, Agnese Chiara Pippione, Iole Mannella, Mariia Iakovleva, Stefano Sainas, Simonetta Oliaro Bosso, Barbara Rolando, Sandra Kovachka, Francesca Spyrakis, Marco Lucio Lolli, Donatella Boschi | |
| New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer | 2021 | Mannella, Iole, Vigato, Chiara, Pasha, Rabia; Pippione Agnese Chiara, Sainas, Stefano, Oliaro Bosso Simonetta; Rolando, Barbara; Kovachka, Sandra, Spyrakis, Francesca; Boschi, Donatella, Lolli. Marco Lucio | |
| Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies | 2023 | Iole Mannella, Chiara Vigato, Stefano Sainas, Marco Lucio Lolli, Donatella Boschi | |
| Optimization of MEDS433 synthesis: scale-up for preclinical evaluation studies | 2023 | Iole Mannella, Chiara Vigato, Stefano Sainas, Marco Lucio Lolli, Donatella Boschi | |
| Overcoming of metabolic issues in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase: the story of MEDS700 | 2024 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Agnese Chiara Pippione, Alice Passoni, Renzo Bagnati, Paola Circosta, Marta Alberti, Riccardo Miggiano, Donatella Boschi, Marco Lucio Lolli | |
| Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic | 2022 | Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Riccardo Miggiano, Davide Ferraris, Marta Alberti, Agnese Chiara Pippione, Chiara Vigato, Donatella Boschi, Giuseppe Saglio, Marco Lucio Lolli | |
| Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic | 2022 | Marta Giorgis, Stefano Sainas, Paola Circosta, Alice Passoni, Renzo Bagnati, Marilena Marraudino, Brigitta Bonaldo, Stefano Gotti, Riccardo Miggiano, Davide Ferraris, Marta Alberti, Agnese Chiara Pippione, Chiara Vigato, Donatella Boschi, Giuseppe Nicola Saglio, Marco Lucio Lolli | |
| Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues | 2021 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione; Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli | |
| Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues | 2021 | Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione, Renzo Bagnati, Giuseppe Saglio, Donatella Boschi, Marco Lucio Lolli. |